Literature DB >> 16014752

Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates.

George A Ricaurte1, Annis O Mechan, Jie Yuan, George Hatzidimitriou, Tao Xie, Andrew H Mayne, Una D McCann.   

Abstract

Pharmacotherapy with amphetamine is effective in the management of attention-deficit/hyperactivity disorder (ADHD), now recognized in adults as well as in children and adolescents. Here we demonstrate that amphetamine treatment, similar to that used clinically for adult ADHD, damages dopaminergic nerve endings in the striatum of adult nonhuman primates. Furthermore, plasma concentrations of amphetamine associated with dopaminergic neurotoxicity in nonhuman primates are on the order of those reported in young patients receiving amphetamine for the management of ADHD. These findings may have implications for the pathophysiology and treatment of ADHD. Further preclinical and clinical studies are needed to evaluate the dopaminergic neurotoxic potential of therapeutic doses of amphetamine in children as well as adults.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014752     DOI: 10.1124/jpet.105.087916

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Dopaminergic system dysfunction in recreational dexamphetamine users.

Authors:  Anouk Schrantee; Lena Václavů; Dennis F R Heijtel; Matthan W A Caan; Willy Gsell; Paul J Lucassen; Aart J Nederveen; Jan Booij; Liesbeth Reneman
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 2.  Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Authors:  S M Berman; R Kuczenski; J T McCracken; E D London
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 4.  A review of psychostimulant-induced neuroadaptation in developing animals.

Authors:  Normand Carrey; Michael Wilkinson
Journal:  Neurosci Bull       Date:  2011-06       Impact factor: 5.203

Review 5.  Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Authors:  Stephen J Kish; Isabelle Boileau; Russell C Callaghan; Junchao Tong
Journal:  Eur J Neurosci       Date:  2016-09-05       Impact factor: 3.386

6.  Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescents.

Authors:  James M Bjork; Gang Chen; Ashley R Smith; Daniel W Hommer
Journal:  J Child Psychol Psychiatry       Date:  2009-12-11       Impact factor: 8.982

7.  D-Amphetamine Exposure Differentially Disrupts Signaling Across Ontogeny in the Zebrafish.

Authors:  Bradley J Serpa; Jennifer D Bullard; Victoria C Mendiola; Crystal J Smith; Brandon Stewart; Lisa R Ganser
Journal:  Bioelectricity       Date:  2019-06-14

8.  Effects of methylphenidate on the aggressive behavior, serotonin and dopamine levels, and dopamine-related gene transcription in brain of male Nile tilapia (Oreochromis niloticus).

Authors:  Isabela Gertrudes Batalhão; Daína Lima; Ana Paula Montedor Russi; Camila Nomura Pereira Boscolo; Danilo Grunig Humberto Silva; Thiago Scremin Boscolo Pereira; Afonso Celso Dias Bainy; Eduardo Alves de Almeida
Journal:  Fish Physiol Biochem       Date:  2019-05-03       Impact factor: 2.794

Review 9.  Abuse of amphetamines and structural abnormalities in the brain.

Authors:  Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Parkinsonism in patients with a history of amphetamine exposure.

Authors:  Chadwick W Christine; Elisabeth R Garwood; Lauren E Schrock; Daniel E Austin; Charles E McCulloch
Journal:  Mov Disord       Date:  2010-01-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.